Patents by Inventor James G. Douglass, III
James G. Douglass, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8158776Abstract: This invention is directed to a method of enhancing or facilitating the clearance or the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is further directed to a method of preventing or treating diseases or conditions associated with impaired lung or airway function in a human or other mammal. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y6 receptor agonist compound, wherein said amount is effective to activate the P2Y6 receptors on the luminal surface of lung epithelia. The P2Y6 receptor agonist compounds useful for this invention include mononucleoside 5?-diphosphates, dinucleoside monophosphate, dinucleoside diphosphates, or dinucleoside triphosphates of general Formula I, or salts, solvates, hydrates thereof. This invention is also directed to novel P2Y6 receptor agonist compounds.Type: GrantFiled: November 4, 2010Date of Patent: April 17, 2012Assignee: Inspire Pharmaceuticals, Inc.Inventors: José L. Boyer, Sammy R. Shaver, James G. Douglass, III, Catherine C. Redick
-
Patent number: 7943760Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.Type: GrantFiled: September 2, 2009Date of Patent: May 17, 2011Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Patent number: 7932376Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide pyrimidine-based compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and Ia-Ic, or tautomers, salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and Ia-Ic.Type: GrantFiled: April 28, 2006Date of Patent: April 26, 2011Assignee: Inspire Pharmaceuticals, Inc.Inventors: James G. Douglass, III, Paul S. Watson, Sammy R. Shaver, Krzysztof Bednarski
-
Publication number: 20110054163Abstract: This invention is directed to a method of enhancing or facilitating the clearance or the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is further directed to a method of preventing or treating diseases or conditions associated with impaired lung or airway function in a human or other mammal. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y6 receptor agonist compound, wherein said amount is effective to activate the P2Y6 receptors on the luminal surface of lung epithelia. The P2Y6 receptor agonist compounds useful for this invention include mononucleoside 5?-diphosphates, dinucleoside monophosphate, dinucleoside diphosphates, or dinucleoside triphosphates of general Formula I, or salts, solvates, hydrates thereof. This invention is also directed to novel P2Y6 receptor agonist compounds.Type: ApplicationFiled: November 4, 2010Publication date: March 3, 2011Inventors: José L. Boyer, Sammy R. Shaver, James G. Douglass, III, Catherine C. Redick
-
Patent number: 7851456Abstract: This invention is directed to a method of enhancing or facilitating the clearance of the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is further directed to a method of preventing or treating diseases or conditions associated with impaired lung or airway function in a human or other mammal. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y6 receptor agonist compound, wherein said amount is effective to activate the P2Y6 receptors on the luminal surface of lung epithelia. The P2Y6 receptor agonist compounds useful for this invention include mononucleoside 5?-diphosphates, dinucleoside monophosphate, dinucleoside diphosphates, or dinucleoside triphosphates of general Formula I, or salts, solvates, hydrates thereof.Type: GrantFiled: June 28, 2006Date of Patent: December 14, 2010Assignee: Inspire Pharmaceuticals, Inc.Inventors: José L. Boyer, Sammy R. Shaver, James G. Douglass, III, Catherine C. Redick
-
Publication number: 20100197913Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.Type: ApplicationFiled: September 2, 2009Publication date: August 5, 2010Inventors: Robert Plourde, JR., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Patent number: 7749981Abstract: The present invention provides a drug-eluting stent, wherein the stent is coated with one or more non-nucleotide P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.Type: GrantFiled: November 4, 2005Date of Patent: July 6, 2010Assignee: Inspire Pharmaceuticals, Inc.Inventors: José L. Boyer, James G. Douglass, III, Sammy R. Shaver
-
Publication number: 20100160250Abstract: This invention provides a method for inhibiting the release of interleukin-1? in a mammal. This invention also provides a method for preventing or treating pulmonary diseases, ophthalmic diseases, and autoimmune diseases that are associated with inflammation or inflammatory conditions. The invention also provides a method for preventing or treating neurodegenerative diseases, or pain in a mammal. The method comprises administering to a mammal in need thereof a therapeutically effective amount of a mononucleoside compound, which is an antagonist of P2X7 receptor.Type: ApplicationFiled: December 17, 2009Publication date: June 24, 2010Inventors: James G. Douglass, III, Sammy R. Shaver, Tomas Navratil, José L. Boyer, Carl A. Samuelson, Jonathan B. DeCamp
-
Patent number: 7741473Abstract: The present invention is directed to a processes for the synthesis of trans isomer of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles (Formula I). The process comprises the steps of: (a) obtaining a compound of Formula II, which is a mixture of cis and trans-diastereomers, and (b) chemically decomposing the compound of Formula II in a solution comprising a solvent and an acid that is a hydrogen donor or an electron pair acceptor, whereby the cis diastereomer is decomposed and the compound of Formula I is obtained. The compounds prepared by the present invention are useful in treating diseases or conditions associated with platelet aggregation and/or platelet activation.Type: GrantFiled: March 30, 2006Date of Patent: June 22, 2010Assignee: Inspire Pharmaceuticals, Inc.Inventors: Paul S. Watson, James G. Douglass, III, Bob Suchozak, Subramanian Pandiaraju, Craig E. Dixon, Daniel Levin
-
Patent number: 7618949Abstract: The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.Type: GrantFiled: July 30, 2008Date of Patent: November 17, 2009Assignees: Inspire Pharmaceuticals, Inc., University of North Carolina at Chapel HillInventors: José L. Boyer, James G. Douglass, III, Sammy R. Shaver
-
Patent number: 7612047Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.Type: GrantFiled: September 10, 2008Date of Patent: November 3, 2009Assignee: Inspire Pharmaceuticals, Inc.Inventors: James G. Douglass, III, Benjamin R. Yerxa, Sammy R. Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean, José L. Boyer
-
Patent number: 7592445Abstract: This invention is directed to compounds of Formulae III and V, useful for treating diseases or conditions associated with platelet aggregation.Type: GrantFiled: January 4, 2008Date of Patent: September 22, 2009Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Publication number: 20090076256Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.Type: ApplicationFiled: September 10, 2008Publication date: March 19, 2009Inventors: James G. Douglass, III, Benjamin R. Yerxa, Sammy R. Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean, Jose L. Boyer
-
Patent number: 7504497Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae III, IIIa, and IIIb, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae IIIa and IIIb, which are potent and have a good oral bioavailability.Type: GrantFiled: November 9, 2006Date of Patent: March 17, 2009Assignee: Inspire Pharmaceuticals, Inc.Inventors: James G. Douglass, III, Paul S. Watson, Carl A. Samuelson, Christopher S. Crean
-
Publication number: 20080287671Abstract: The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.Type: ApplicationFiled: July 30, 2008Publication date: November 20, 2008Inventors: Jose L. Boyer, James G. Douglass, III, Sammy R. Shaver
-
Patent number: 7452870Abstract: The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.Type: GrantFiled: November 4, 2005Date of Patent: November 18, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventors: José L. Boyer, James G. Douglass, III, Sammy R. Shaver
-
Patent number: 7435724Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.Type: GrantFiled: November 21, 2005Date of Patent: October 14, 2008Assignee: Inspire Pharmaceutical, Inc.Inventors: James G. Douglass, III, Benjamin R. Yerxa, Sammy R. Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean, José L. Boyer
-
Patent number: 7335648Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.Type: GrantFiled: May 5, 2005Date of Patent: February 26, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Patent number: 7132408Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y12 receptor antagonist compound, wherein said amount is effective to bind the P2Y12 receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12 receptor antagonist compounds useful for this invention include mononucleoside 5?-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates of general Formula I, or salts thereof. The present invention also provides novel compounds of mononucleoside 5?-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates. The present invention further provides pharmaceutical formulations comprising mononucleoside 5?-monophosphates, mononucleoside polyphosphates, or dinucleoside polyphosphates.Type: GrantFiled: March 30, 2004Date of Patent: November 7, 2006Assignees: Inspire Pharmaceuticals, Inc., University of North CarolinaInventors: José L. Boyer, James G. Douglass, III, Sammy R. Shaver, Krzysztof Bednarski, Benjamin R. Yerxa, Gillian M. Olins
-
Patent number: 7115585Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides.Type: GrantFiled: February 27, 2002Date of Patent: October 3, 2006Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, James G. Douglass, III, Sammy Ray Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean